US FDA cites four deaths behind Newron schizophrenia trial hold
Newron Pharmaceuticals said the US FDA outlined safety concerns behind a clinical hold at US sites in a late-stage schizophrenia-drug trial, citing four deaths and irregular heart rhythms.